Trials / Completed
CompletedNCT03656211
Fertility After Diagnosis and Management of Acquired Uterine Arteriovenous Malformation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 15 (actual)
- Sponsor
- Rennes University Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Uterine arteriovenous malformations (UAVM) are short circuits between systemic arterial and venous networks within the uterus. They are congenital or acquired (in the course of an endo-uterine gesture such as curettage or interventions such as caesareans or myomectomies). They can be manifested by severe metrorrhagia that can go as far as to put the patient's vital prognosis at risk. There are no recommendations for the management of UAVM since this pathology is rare and therefore series are performed with few cases. If some of these UAVM disappear spontaneously after a therapeutic abstention, when the clinical context allows it, in case of symptomatic UAVM, a selective embolization with arteriography is often carried out to postpone the hysterectomy of hemostasis. There are also more marginal management options such as Gonadotropin-Releasing Hormone agonists, methotrexate or curettage that are decided on a case by case basis depending on the symptoms and protocols of each medical team. Regarding subsequent fertility and pregnancy outcomes after conservative treatment, the number of studies is even lower.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Telephone interview | Patients are contacted by telephone to know the history of the disease since the diagnosis of UAVM and the impact of management on fertility. All medical data related to the care and necessary for the study are collected from the medical file the participation of the patients is limited to a telephone interview. |
Timeline
- Start date
- 2017-10-02
- Primary completion
- 2017-10-10
- Completion
- 2017-10-10
- First posted
- 2018-09-04
- Last updated
- 2018-09-04
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03656211. Inclusion in this directory is not an endorsement.